成人癲癇伴焦慮的研究進展_Journal of Epilepsy

Authors：

臧學革 ¹ , 喬慧 ¹ , 馮曉娜 ¹ , 陳艷艷 ² ,  王立波 ¹

1. ;
2. ;

Corresponding?author：

王立波, Email: 935583975@qq.com

Keywords：

DOI：

10.7507/2096-0247.20200072

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

大量流行病學研究表明焦慮性障礙（Anxiety disorder，AD）在癲癇患者中的患病率高于普通人群，AD 不僅能增加癲癇患者的自殺風險，還可導致疾病進一步惡化。目前，我國對于成人癲癇伴焦慮的研究仍不成熟，臨床醫生對于癲癇患者共患焦慮仍缺乏進一步的認識，使得臨床上誤診率高，患者病情未能得到及時的治療。文章結合國內外最新研究，對成人癲癇伴焦慮的危險因素、發病機制、分類、診斷、鑒別診斷、篩查、治療等方面作一綜述，為臨床診治提供參考。

Citation： 臧學革, 喬慧, 馮曉娜, 陳艷艷, 王立波. 成人癲癇伴焦慮的研究進展. Journal of Epilepsy, 2020, 6(5): 436-442. doi: 10.7507/2096-0247.20200072 Copy

1.	Hesdorffer DC, Ishihara L, Mynepalli L, <italic>et al</italic>. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol, 2012, 72(2): 184-191.
2.	Bourdon KH, Rae DS, Locke BZ, <italic>et al</italic>. Estimating the prevalence of mental disorders in US adults from the Epidemiologic Catchment Area Survey. Public Health Rep, Nov-Dec 1992, 107(6): 663-668.
3.	Kessler RC, Petukhova M, Sampson NA, <italic>et al</italic>. Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res, 2012, 21(3): 169-184.
4.	Alonso J, Lepine JP. Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry, 2007, 68(Suppl 2): 3-9.
5.	Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe–a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol, 2005, 15(4): 357-376.
6.	Huang Y, Wang Y, Wang H, <italic>et al</italic>. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
7.	Yang TW, Kim DH, Kim YS, <italic>et al</italic>. Anxiety disorders in outpatient clinics of epilepsy in tertiary care hospitals: A meta-analysis. Seizure, 2020, 75: 34-42.
8.	Baxter AJ, Scott KM, Vos T, <italic>et al</italic>. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med, 2013, 43: 897-910.
9.	Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51(5): 355-364.
10.	Jansen C, Francomme L, Vignal JP, <italic>et al</italic>. Interictal psychiatric comorbidities of drug-resistant focal epilepsy: Prevalence and influence of the localization of the epilepsy. Epilepsy Behav, 2019, 94: 288-296.
11.	Gandy M, Sharpe L, Perry KN, <italic>et al</italic>. Rates of DSM-IV mood, anxiety disorders, and suicidality in Australian adult epilepsy outpatients: a comparison of well-controlled versus refractory epilepsy. Epilepsy Behav, 2013, 26: 29-35.
12.	Rai D, Kerr MP, McManus S, <italic>et al</italic>. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia, 2012, 53(7): 1095-1103.
13.	Scott AJ, Sharpe L, Hunt C, <italic>et al</italic>. Anxiety and depressive disorders in people with epilepsy: A meta-analysis. Epilepsia, 2017, 58(6): 973-982.
14.	Tellez-Zenteno JF, Patten SB, Jetté N, <italic>et al</italic>. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia, 2007, 48(12): 2336-2344.
15.	Jones JE, Hermann BP, Barry JJ, <italic>et al</italic>. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci, 2005, 17(2): 172-179.
16.	Brandt C, Mula M. Anxiety disorders in people with epilepsy. Epilepsy Behav, 2016, 59: 87-91.
17.	Tang WK, Lu J, Ungvari GS, <italic>et al</italic>. Anxiety symptoms in patients with frontal lobe epilepsy versus generalized epilepsy. Seizure, 2012, 21(6): 457-460.
18.	Jacoby A, Baker GA, Steen N, <italic>et al</italic>. The clinical course of epilepsy and its psychosocial correlates: findings from a U. K. Community study. Epilepsia, 1996, 37(2): 148-161.
19.	Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand, 2004, 110(4): 207-220.
20.	Gaitatzis A, Carroll K, Majeed A, <italic>et al</italic>. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia, 2004, 45(12): 1613-1622.
21.	Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 Health Styles Survey. Epilepsia, 2006, 47(11): 1915-1921.
22.	Hingray C, McGonigal A, Kotwas I, <italic>et al</italic>. The relationship between epilepsy and anxiety disorders. Curr Psychiatry Rep, 2019, 21(6): 40.
23.	Kanner AM. Anxiety disorders in epilepsy: the forgotten psychiat-ric comorbidity. Epilepsy Curr, 2011, 11(3): 90-91.
24.	Kanner AM, Barry JJ, Gilliam F, <italic>et al</italic>. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia, 2012, 53(6): 1104-1108.
25.	Velissaris SL, Wilson SJ, Newton MR, <italic>et al</italic>. Cognitive complaints after a first seizure in adulthood: Influence of psychological adjustment. Epilepsia, 2009, 50(5): 1012-1021.
26.	Kanner AM, Byrne R, Chicharro A, <italic>et al</italic>. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology, 2009, 72(9): 793-799.
27.	Petrovski S, Szoeke CE, Jones NC, <italic>et al</italic>. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology, 2010, 75(11): 1015-1021.
28.	Hamilton KT, Anderson CT, Dahodwala N, <italic>et al</italic>. Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression. Seizure, 2014, 23(3): 196-200.
29.	Noble AJ, Goldstein LH, Seed P, <italic>et al</italic>. Characteristics of people with epilepsy who attend emergency departments: prospective study of metropolitan hospital attendees. Epilepsia, 2012, 53(10): 1820-1828.
30.	Choi-Kwon S, Chung C, Kim H, <italic>et al</italic>. Factors affecting the quality of life in patients with epilepsy in Seoul, South Korea. Acta Neurol Scand, 2003, 108(6): 428-434.
31.	Pham T, Sauro KM, Patten SB, <italic>et al</italic>. The prevalence of anxiety and associated factors in persons with epilepsy. Epilepsia, 2017, 58(8): e107-e110.
32.	Munger Clary HM, Snively BM, Hamberger MJ. Anxiety is common and independently associated with clinical features of epilepsy. Epilepsy Behav, 2018, 85: 64-71.
33.	Wang HJ, Tan G, Deng Y, <italic>et al</italic>. Prevalence and risk factors of depression and anxiety among patients with convulsive epilepsy in rural West China. Acta Neurol Scand, 2018, 138(6): 541-547.
34.	Bj?rk MH, Veiby G, Reiter SC, <italic>et al</italic>. Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis. Epilepsia, 2015, 56(1): 28-39.
35.	Stahl SM. Brainstorms: symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry, 2003, 64(12): 1408-1409.
36.	Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol, 2007, 27(3): 263-272.
37.	Shaw FZ, Chuang SH, Shieh KR, <italic>et al</italic>. Depression-and anxiety-like behaviors of a rat model with absence epileptic discharges. Neuroscience, 2009, 160(2): 382-393.
38.	Duarte FS, Duzzioni M, Hoeller AA, <italic>et al</italic>. Anxiogenic-like profile of Wistar adult rats based on the pilocarpine model: an animal model for trait anxiety? Psychopharmacology (Berl), 2013, 227(2): 209-219.
39.	Kanner AM, Schachter SC, Barry JJ, <italic>et al</italic>. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav, 2012, 24: 156-168.
40.	Munger Clary HM, Salpekar JA. Should adult neurologists play a role in the management of the most common psychiatric comorbid-ities?. Practical considerations. Epilepsy Behav, 2019, 98(Pt B): 309-313.
41.	de Toffol B, Hingray C, Biberon J, <italic>et al</italic>. Psychiatric comor-bidities in epilepsy. Presse Med, 2018, 47(3): 243-250.
42.	Kanner AM. Ictal panic and interictal panic attacks: diagnostic and therapeutic principles. Neurol Clin, 2011, 29(1): 163-175.
43.	American Psychiatric Association. Diagnostic and statistical manual for mental disorders-IV-TR. Arlington (VA): American Psychiatric Publishing, 1994: 1-915.
44.	American Psychiatric Association. Diagnostic and statistical manual for mental disorders-5. Arlington (VA): American Psychiatric Publishing, 2013: 1-970.
45.	Cleary RA, Baxendale SA, Thompson PJ, <italic>et al</italic>. Predicting and preventing psychopathology following temporal lobe epilepsy sur-gery. Epilepsy Behav, 2013, 26: 322-334.
46.	Jones JE, Hermann BP, Barry JJ, <italic>et al</italic>. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci, 2014, 17(2): 172-179.
47.	Cohen JF, Korevaar DA, Altman DG, <italic>et al</italic>. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open, 2016, 6(11): e012799.
48.	Brown TA, Campbell LA, Lehman CL, <italic>et al</italic>. Current and lifetime co-morbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol, 2001, 110(4): 585.
49.	Bias AR. QUADAS 2. Am J Gastroenterol, 2012, 107: 1354-1360.
50.	Wang Z, Luo Z, Li S, <italic>et al</italic>. Anxiety screening tools in people with epilepsy: A systematic review of validated tools. Epilepsy Behav, 2019, 99: 106392.
51.	Sheehan DV, Lecrubier Y, Sheehan KH, <italic>et al</italic>. The va-lidity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry, 1997, 12(5): 232-241.
52.	Fiest KM, Patten SB, Jetté N. Screening for Depression and Anxiety in Epilepsy. Neurol Clin, 2016, 34(2): 351-361.
53.	Kroenke K, Spitzer, R L, Williams JB, <italic>et al</italic>. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med, 2007, 146(5): 317-325.
54.	Tong X, An D, McGonigal A, <italic>et al</italic>. Validation of the generalized anxiety disorder-7 (GAD-7) among Chinese people with epilepsy. Epilepsy Res, 2016, 120: 31-36.
55.	Munger Clary HM, Croxton RD, Allan J, <italic>et al</italic>. Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic. Epilepsy Behav, 2020, 104(Pt A): 106907.
56.	Scott AJ, Sharpe L, Thayer Z, <italic>et al</italic>. Design and validation of two measures to detect anxiety disorders in epilepsy: The Epilepsy Anxiety Survey Instrument and its brief counterpart. Epilepsia, 2019, 60(10): 2068-2077.
57.	Stern AF. The hospital anxiety and depression scale. Occup Med (Chic Ill), 2014, 67(6): 361.
58.	Gandy M, Sharpe L, Perry KN, <italic>et al</italic>. Anxiety in epilepsy: a neglected disorder. J Psychosom Res, 2015, 78(2): 149-155.
59.	中國抗癲癇協會共患病專業委員會. 癲癇伴焦慮診斷治療的中國專家共識. 癲癇雜志, 2018, 4(3): 7-13.
60.	Mula M, Schmitz B, Jauch R, <italic>et al</italic>. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav, 2008, 13(4): 658-661.
61.	Guimond A, Braun CM, Bélanger E, <italic>et al</italic>. Ictal fear depends on the cerebral laterality of the epileptic activity. Epileptic Disord, 2008, 10(2): 101-112.
62.	Oehl B, Schulze-Bonhage A, Lanz M, <italic>et al</italic>. Occipital lobe epilepsy with fear as leading ictal symptom. Epilepsy Behav, 2012, 23: 379-383.
63.	Satishchandra P, Krishnamoorthy ES, van Elst LT, <italic>et al</italic>. Mesial temporal structures and comorbid anxiety in refractory partial epilepsy. J Neuropsychiatry Clin Neurosci, 2003, 15(4): 450-452.
64.	Mula M. Pharmacological treatment of anxiety disorders in adults with epilepsy. Expert Opin Pharmacother, 2018, 19(17): 1867-1874.
65.	Mula M. Treatment of anxiety disorders in epilepsy: an evidence-based approach. Epilepsia, 2013, 54(Suppl 1): 13-18.
66.	Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol, 2011, 14(5): 697-710.
67.	Baldwin DS, Anderson IM, Nutt DJ, <italic>et al</italic>. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl, 2014, 28(5): 403-439.
68.	Thanacoody HKR, Thomas SHL. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev, 2005, 24(3): 205-214.
69.	Kerr MP, Mensah S, Besag F, <italic>et al</italic>. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia, 2011, 52(11): 2133-2138.
70.	Brandt C, Schoendienst M, Trentowska M, <italic>et al</italic>. Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders-results of an open-label, parallel group, investigator-initiated, proof-of-concept study. Epilepsy Behav, 2013, 29: 298-304.
71.	Munger Clary HM. Anxiety and epilepsy: what neurologists and epileptologists should know. Curr Neurol Neurosci Rep, 2014, 14(5): 445.
72.	Hagemann A, May TW, Nieder E, <italic>et al</italic>. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Res, 2013, 104(1-2): 140-150.
73.	Mula M, Trimble MR, Yuen A, <italic>et al</italic>. Psychiatric adverse events during levetiracetam therapy. Neurology, 2003, 61(5): 704-706.
74.	Kotwas I, McGonigal A, Trebuchon A, <italic>et al</italic>. Self-control of epileptic seizures by nonpharmacological strategies. Epilepsy Behav, 2016, 55: 157-164.
75.	Hofmann SG, Sawyer A T, Witt AA, <italic>et al</italic>. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol, 2010, 78(2): 169-183.
76.	Dewhurst E, Novakova B, Reuber M. A prospective service evalu-ation of acceptance and commitment therapy for patients with re-fractory epilepsy. Epilepsy Behav, 2015, 46: 234-241.
77.	Tang V, Poon WS, Kwan P. Mindfulness-based therapy for drug-resistant epilepsy an assessor-blinded randomized trial. Neurology, 2015, 85(13): 1100-1107.
78.	Thompson NJ, Patel AH, Selwa LM, <italic>et al</italic>. Expanding the efficacy of project UPLIFT: distance de-livery of mindfulness-based depression prevention to people with epilepsy. J Consult Clin Psychol, 2015, 83(2): 304-313.
79.	Macrodimitris S, Wershler J, Hatfield M, <italic>et al</italic>. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. Epilepsy Behav, 2011, 20: 83-88.
80.	Baxendale S, O'Sullivan J, Heaney D. Bright light therapy for symptoms of anxiety and depression in focal epilepsy: randomised controlled trial. Br J Psychiatry, 2013, 202(5): 352-356.
81.	Zheng Y, Ding X, Guo Y, <italic>et al</italic>. Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study. Epilepsy Behav, 2019, 100(Pt A): 106400.

1. Hesdorffer DC, Ishihara L, Mynepalli L, <italic>et al</italic>. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol, 2012, 72(2): 184-191.
2. Bourdon KH, Rae DS, Locke BZ, <italic>et al</italic>. Estimating the prevalence of mental disorders in US adults from the Epidemiologic Catchment Area Survey. Public Health Rep, Nov-Dec 1992, 107(6): 663-668.
3. Kessler RC, Petukhova M, Sampson NA, <italic>et al</italic>. Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res, 2012, 21(3): 169-184.
4. Alonso J, Lepine JP. Overview of key data from the European study of the epidemiology of mental disorders (ESEMeD). J Clin Psychiatry, 2007, 68(Suppl 2): 3-9.
5. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe–a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol, 2005, 15(4): 357-376.
6. Huang Y, Wang Y, Wang H, <italic>et al</italic>. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry, 2019, 6(3): 211-224.
7. Yang TW, Kim DH, Kim YS, <italic>et al</italic>. Anxiety disorders in outpatient clinics of epilepsy in tertiary care hospitals: A meta-analysis. Seizure, 2020, 75: 34-42.
8. Baxter AJ, Scott KM, Vos T, <italic>et al</italic>. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med, 2013, 43: 897-910.
9. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 1994, 51(5): 355-364.
10. Jansen C, Francomme L, Vignal JP, <italic>et al</italic>. Interictal psychiatric comorbidities of drug-resistant focal epilepsy: Prevalence and influence of the localization of the epilepsy. Epilepsy Behav, 2019, 94: 288-296.
11. Gandy M, Sharpe L, Perry KN, <italic>et al</italic>. Rates of DSM-IV mood, anxiety disorders, and suicidality in Australian adult epilepsy outpatients: a comparison of well-controlled versus refractory epilepsy. Epilepsy Behav, 2013, 26: 29-35.
12. Rai D, Kerr MP, McManus S, <italic>et al</italic>. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia, 2012, 53(7): 1095-1103.
13. Scott AJ, Sharpe L, Hunt C, <italic>et al</italic>. Anxiety and depressive disorders in people with epilepsy: A meta-analysis. Epilepsia, 2017, 58(6): 973-982.
14. Tellez-Zenteno JF, Patten SB, Jetté N, <italic>et al</italic>. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia, 2007, 48(12): 2336-2344.
15. Jones JE, Hermann BP, Barry JJ, <italic>et al</italic>. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci, 2005, 17(2): 172-179.
16. Brandt C, Mula M. Anxiety disorders in people with epilepsy. Epilepsy Behav, 2016, 59: 87-91.
17. Tang WK, Lu J, Ungvari GS, <italic>et al</italic>. Anxiety symptoms in patients with frontal lobe epilepsy versus generalized epilepsy. Seizure, 2012, 21(6): 457-460.
18. Jacoby A, Baker GA, Steen N, <italic>et al</italic>. The clinical course of epilepsy and its psychosocial correlates: findings from a U. K. Community study. Epilepsia, 1996, 37(2): 148-161.
19. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand, 2004, 110(4): 207-220.
20. Gaitatzis A, Carroll K, Majeed A, <italic>et al</italic>. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia, 2004, 45(12): 1613-1622.
21. Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 Health Styles Survey. Epilepsia, 2006, 47(11): 1915-1921.
22. Hingray C, McGonigal A, Kotwas I, <italic>et al</italic>. The relationship between epilepsy and anxiety disorders. Curr Psychiatry Rep, 2019, 21(6): 40.
23. Kanner AM. Anxiety disorders in epilepsy: the forgotten psychiat-ric comorbidity. Epilepsy Curr, 2011, 11(3): 90-91.
24. Kanner AM, Barry JJ, Gilliam F, <italic>et al</italic>. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia, 2012, 53(6): 1104-1108.
25. Velissaris SL, Wilson SJ, Newton MR, <italic>et al</italic>. Cognitive complaints after a first seizure in adulthood: Influence of psychological adjustment. Epilepsia, 2009, 50(5): 1012-1021.
26. Kanner AM, Byrne R, Chicharro A, <italic>et al</italic>. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology, 2009, 72(9): 793-799.
27. Petrovski S, Szoeke CE, Jones NC, <italic>et al</italic>. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology, 2010, 75(11): 1015-1021.
28. Hamilton KT, Anderson CT, Dahodwala N, <italic>et al</italic>. Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression. Seizure, 2014, 23(3): 196-200.
29. Noble AJ, Goldstein LH, Seed P, <italic>et al</italic>. Characteristics of people with epilepsy who attend emergency departments: prospective study of metropolitan hospital attendees. Epilepsia, 2012, 53(10): 1820-1828.
30. Choi-Kwon S, Chung C, Kim H, <italic>et al</italic>. Factors affecting the quality of life in patients with epilepsy in Seoul, South Korea. Acta Neurol Scand, 2003, 108(6): 428-434.
31. Pham T, Sauro KM, Patten SB, <italic>et al</italic>. The prevalence of anxiety and associated factors in persons with epilepsy. Epilepsia, 2017, 58(8): e107-e110.
32. Munger Clary HM, Snively BM, Hamberger MJ. Anxiety is common and independently associated with clinical features of epilepsy. Epilepsy Behav, 2018, 85: 64-71.
33. Wang HJ, Tan G, Deng Y, <italic>et al</italic>. Prevalence and risk factors of depression and anxiety among patients with convulsive epilepsy in rural West China. Acta Neurol Scand, 2018, 138(6): 541-547.
34. Bj?rk MH, Veiby G, Reiter SC, <italic>et al</italic>. Depression and anxiety in women with epilepsy during pregnancy and after delivery: a prospective population-based cohort study on frequency, risk factors, medication, and prognosis. Epilepsia, 2015, 56(1): 28-39.
35. Stahl SM. Brainstorms: symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry, 2003, 64(12): 1408-1409.
36. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol, 2007, 27(3): 263-272.
37. Shaw FZ, Chuang SH, Shieh KR, <italic>et al</italic>. Depression-and anxiety-like behaviors of a rat model with absence epileptic discharges. Neuroscience, 2009, 160(2): 382-393.
38. Duarte FS, Duzzioni M, Hoeller AA, <italic>et al</italic>. Anxiogenic-like profile of Wistar adult rats based on the pilocarpine model: an animal model for trait anxiety? Psychopharmacology (Berl), 2013, 227(2): 209-219.
39. Kanner AM, Schachter SC, Barry JJ, <italic>et al</italic>. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav, 2012, 24: 156-168.
40. Munger Clary HM, Salpekar JA. Should adult neurologists play a role in the management of the most common psychiatric comorbid-ities?. Practical considerations. Epilepsy Behav, 2019, 98(Pt B): 309-313.
41. de Toffol B, Hingray C, Biberon J, <italic>et al</italic>. Psychiatric comor-bidities in epilepsy. Presse Med, 2018, 47(3): 243-250.
42. Kanner AM. Ictal panic and interictal panic attacks: diagnostic and therapeutic principles. Neurol Clin, 2011, 29(1): 163-175.
43. American Psychiatric Association. Diagnostic and statistical manual for mental disorders-IV-TR. Arlington (VA): American Psychiatric Publishing, 1994: 1-915.
44. American Psychiatric Association. Diagnostic and statistical manual for mental disorders-5. Arlington (VA): American Psychiatric Publishing, 2013: 1-970.
45. Cleary RA, Baxendale SA, Thompson PJ, <italic>et al</italic>. Predicting and preventing psychopathology following temporal lobe epilepsy sur-gery. Epilepsy Behav, 2013, 26: 322-334.
46. Jones JE, Hermann BP, Barry JJ, <italic>et al</italic>. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci, 2014, 17(2): 172-179.
47. Cohen JF, Korevaar DA, Altman DG, <italic>et al</italic>. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open, 2016, 6(11): e012799.
48. Brown TA, Campbell LA, Lehman CL, <italic>et al</italic>. Current and lifetime co-morbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. J Abnorm Psychol, 2001, 110(4): 585.
49. Bias AR. QUADAS 2. Am J Gastroenterol, 2012, 107: 1354-1360.
50. Wang Z, Luo Z, Li S, <italic>et al</italic>. Anxiety screening tools in people with epilepsy: A systematic review of validated tools. Epilepsy Behav, 2019, 99: 106392.
51. Sheehan DV, Lecrubier Y, Sheehan KH, <italic>et al</italic>. The va-lidity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry, 1997, 12(5): 232-241.
52. Fiest KM, Patten SB, Jetté N. Screening for Depression and Anxiety in Epilepsy. Neurol Clin, 2016, 34(2): 351-361.
53. Kroenke K, Spitzer, R L, Williams JB, <italic>et al</italic>. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med, 2007, 146(5): 317-325.
54. Tong X, An D, McGonigal A, <italic>et al</italic>. Validation of the generalized anxiety disorder-7 (GAD-7) among Chinese people with epilepsy. Epilepsy Res, 2016, 120: 31-36.
55. Munger Clary HM, Croxton RD, Allan J, <italic>et al</italic>. Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic. Epilepsy Behav, 2020, 104(Pt A): 106907.
56. Scott AJ, Sharpe L, Thayer Z, <italic>et al</italic>. Design and validation of two measures to detect anxiety disorders in epilepsy: The Epilepsy Anxiety Survey Instrument and its brief counterpart. Epilepsia, 2019, 60(10): 2068-2077.
57. Stern AF. The hospital anxiety and depression scale. Occup Med (Chic Ill), 2014, 67(6): 361.
58. Gandy M, Sharpe L, Perry KN, <italic>et al</italic>. Anxiety in epilepsy: a neglected disorder. J Psychosom Res, 2015, 78(2): 149-155.
59. 中國抗癲癇協會共患病專業委員會. 癲癇伴焦慮診斷治療的中國專家共識. 癲癇雜志, 2018, 4(3): 7-13.
60. Mula M, Schmitz B, Jauch R, <italic>et al</italic>. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav, 2008, 13(4): 658-661.
61. Guimond A, Braun CM, Bélanger E, <italic>et al</italic>. Ictal fear depends on the cerebral laterality of the epileptic activity. Epileptic Disord, 2008, 10(2): 101-112.
62. Oehl B, Schulze-Bonhage A, Lanz M, <italic>et al</italic>. Occipital lobe epilepsy with fear as leading ictal symptom. Epilepsy Behav, 2012, 23: 379-383.
63. Satishchandra P, Krishnamoorthy ES, van Elst LT, <italic>et al</italic>. Mesial temporal structures and comorbid anxiety in refractory partial epilepsy. J Neuropsychiatry Clin Neurosci, 2003, 15(4): 450-452.
64. Mula M. Pharmacological treatment of anxiety disorders in adults with epilepsy. Expert Opin Pharmacother, 2018, 19(17): 1867-1874.
65. Mula M. Treatment of anxiety disorders in epilepsy: an evidence-based approach. Epilepsia, 2013, 54(Suppl 1): 13-18.
66. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol, 2011, 14(5): 697-710.
67. Baldwin DS, Anderson IM, Nutt DJ, <italic>et al</italic>. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol Oxf Engl, 2014, 28(5): 403-439.
68. Thanacoody HKR, Thomas SHL. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev, 2005, 24(3): 205-214.
69. Kerr MP, Mensah S, Besag F, <italic>et al</italic>. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia, 2011, 52(11): 2133-2138.
70. Brandt C, Schoendienst M, Trentowska M, <italic>et al</italic>. Efficacy and safety of pregabalin in refractory focal epilepsy with and without comorbid anxiety disorders-results of an open-label, parallel group, investigator-initiated, proof-of-concept study. Epilepsy Behav, 2013, 29: 298-304.
71. Munger Clary HM. Anxiety and epilepsy: what neurologists and epileptologists should know. Curr Neurol Neurosci Rep, 2014, 14(5): 445.
72. Hagemann A, May TW, Nieder E, <italic>et al</italic>. Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. Epilepsy Res, 2013, 104(1-2): 140-150.
73. Mula M, Trimble MR, Yuen A, <italic>et al</italic>. Psychiatric adverse events during levetiracetam therapy. Neurology, 2003, 61(5): 704-706.
74. Kotwas I, McGonigal A, Trebuchon A, <italic>et al</italic>. Self-control of epileptic seizures by nonpharmacological strategies. Epilepsy Behav, 2016, 55: 157-164.
75. Hofmann SG, Sawyer A T, Witt AA, <italic>et al</italic>. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol, 2010, 78(2): 169-183.
76. Dewhurst E, Novakova B, Reuber M. A prospective service evalu-ation of acceptance and commitment therapy for patients with re-fractory epilepsy. Epilepsy Behav, 2015, 46: 234-241.
77. Tang V, Poon WS, Kwan P. Mindfulness-based therapy for drug-resistant epilepsy an assessor-blinded randomized trial. Neurology, 2015, 85(13): 1100-1107.
78. Thompson NJ, Patel AH, Selwa LM, <italic>et al</italic>. Expanding the efficacy of project UPLIFT: distance de-livery of mindfulness-based depression prevention to people with epilepsy. J Consult Clin Psychol, 2015, 83(2): 304-313.
79. Macrodimitris S, Wershler J, Hatfield M, <italic>et al</italic>. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety. Epilepsy Behav, 2011, 20: 83-88.
80. Baxendale S, O'Sullivan J, Heaney D. Bright light therapy for symptoms of anxiety and depression in focal epilepsy: randomised controlled trial. Br J Psychiatry, 2013, 202(5): 352-356.
81. Zheng Y, Ding X, Guo Y, <italic>et al</italic>. Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study. Epilepsy Behav, 2019, 100(Pt A): 106400.

Previous Article
基因啟動子甲基化在癲癇的研究進展
Next Article
繼發于自身免疫性腦炎的急性癥狀性發作和自身免疫相關癲癇：概念性定義

Journal of Epilepsy

成人癲癇伴焦慮的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content